Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
European League Against Rheumatism (EULAR) Congress 2016
June 08 - 11, 2016; London, the United Kingdom
June 08 - 11, 2016London, the United Kingdom
EULARSingle Rituximab Injection Delays RA in High-Risk PatientsA single infusion of the anti-CD20 antibody rituximab, intended to deplete the B-cell population, delays the onset of rheumatoid arthritis in high-risk patients, results from the PRAIRI study suggest.
Medscape Medical News, June 17, 2016
EULARAnti-Interferon Antibody Curbs Lupus Disease ActivityAfter years of clinical trial failures, early evidence suggests an anti-interferon antibody, anifrolumab, reduces disease activity in systemic lupus erythematosus, and it appears to be well tolerated.
Medscape Medical News, June 14, 2016
EULARInflammatory Arthritis Stable After Switch to BiosimilarThe switch to an infliximab biosimilar was not associated with any change in disease activity or worsening of flares, at least in the short term, new research shows.
New Oral Biologic Improves Symptoms in Refractory RAA new oral JAK1/JAK2 inhibitor produces rapid clinical improvement in patients with refractory rheumatoid arthritis (RA),
despite previous exposure to multiple biologic agents.
Medscape Medical News, Jun 18, 2015
Triple Treatment Effective in Early Rheumatoid ArthritisEarly combination therapy leads to earlier sustained remission than monotherapy and preserves functional ability; however,
at 2 years, drug-free remission rates are equivalent, new research shows.
